UnitedHealth Forms Golden Cross After 48% Peak-to-Trough Stock Decline
UnitedHealth Group's stock formed a golden cross as its 50-day moving average crossed above the 200-day following a 48% peak-to-trough decline. This comes after Q4 revenue of $113.2 billion missed estimates by $530 million and 2026 guidance of $439 billion implied a year-over-year decline that sparked a 20% one-day selloff.
1. Lee Financial Co Enters Position in UnitedHealth Group
Lee Financial Co disclosed a new stake in UnitedHealth Group in its latest SEC Form 13F filing for the third quarter. The firm acquired 3,390 shares of the healthcare conglomerate, representing an investment of approximately $1.17 million. This marks Lee Financial’s first reported holding in UnitedHealth, reflecting growing interest in the company’s combined health benefits and services platforms.
2. Broader Institutional Movements Highlight Confidence in Growth
Several other institutional investors have also adjusted holdings in UnitedHealth during recent quarters. Brighton Jones LLC increased its stake by 176.2%, adding 28,231 shares to reach 44,249 shares valued at about $22.38 million. Revolve Wealth Partners LLC boosted its position by 137.1%, purchasing 2,324 shares and holding 4,019 shares worth roughly $2.03 million. In the second quarter, Patriot Financial Group Insurance Agency LLC raised its stake by 42.5% to 5,312 shares ($1.66 million), while Montz Harcus Wealth Management LLC added 74 shares for a 12.2% gain, holding 679 shares valued at $212,000. Overall, 87.86% of UnitedHealth shares remain in institutional hands.
3. Analyst Ratings Paint a ‘Moderate Buy’ Consensus
Wall Street analysts offer a cautiously optimistic outlook for UnitedHealth. Among recent updates, Jefferies lowered its target to $340 and maintained a Buy rating, while Oppenheimer cut its target to $385 but upheld an Outperform call. KeyCorp reiterated an Overweight stance, TD Cowen nudged its target from $335 to $338 with a Hold rating, and Zacks Research moved to Hold from Strong Sell. Of twenty-nine published ratings, seventeen are Buys, nine Holds and two Sells, producing an average consensus of Moderate Buy and mean target near $376.75.
4. Fourth-Quarter Results and 2026 Guidance Underpin Long-Term Thesis
On January 27, UnitedHealth reported fourth-quarter revenue of $113.22 billion, up 12.3% year-on-year but narrowly missing consensus by $0.16 billion. Adjusted EPS of $2.11 marginally exceeded estimates by $0.02. The company’s net margin reached 2.69% and return on equity 14.79%. For fiscal 2026, management set annual EPS guidance at $17.75 and projected revenue of approximately $439 billion, below street forecasts near $454 billion, implying a modest year-over-year contraction. Investors will monitor execution across UnitedHealthcare and Optum segments as the firm seeks to reaccelerate top-line growth while maintaining disciplined expense management.